Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, ...

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Several major U.S. health insurers announce they will voluntarily speed up and simplify the prior authorization process.

The FDA is investigating two deaths in non-ambulatory Duchenne muscular dystrophy patients who received a Sarepta gene ...

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, Zepbound, is viewed when compared to Wegovy.

Eli Lilly increased its revenue from $8,768 million in Q1 2024 to $12,728.5 million in Q1 2025 – resulting in 45.2% year-over-year growth for the top line. ... CVS Health decided a few weeks ...